3ŒŽ27“ú(æ—¥)@9:00~11:30@B‰ïê パシフィコ横浜 会è°ã‚»ãƒ³ã‚¿ãƒ¼ã€€3F 301 S01 日本å¦è¡“会è°è–¬å¦å§”員会医療系薬å¦åˆ†ç§‘会ä¼ç”»è–¬å¦ç ”究ã®ã“ã‚Œã‹ã‚‰ã€€â€•åŸºç¤Žã¨è‡¨åºŠã®æž¶ã‘橋― Pharmaceutical Sciences in the Future: The Linking Bridge between Basic and Clinical Research オーガナイザー:橋田  å……ã€æœ›æœˆ 眞弓 S01-1 基調講演 Keynote lecture ƒVƒ“ƒ|ƒWƒXƒg F â—‹æ‰å±± 雄一 S01-2 レギュラトリーサイエンスã®è¦–点ã‹ã‚‰ From the viewpoint of regulatory science ƒVƒ“ƒ|ƒWƒXƒg F ○長野 哲雄 S01-3 医療ç¾å ´ã®è¦–点ã‹ã‚‰ï¼šãƒªãƒãƒ¼ã‚¹ãƒˆãƒ©ãƒ³ã‚¹ãƒ¬ãƒ¼ã‚·ãƒ§ãƒŠãƒ«ãƒªã‚µãƒ¼ãƒã¨ã—ã¦ã®è–¬å‰¤ç–«å¦ From a view point of clinical settings: pharmacoepidemiology as a reverse translational research (rTR) ƒVƒ“ƒ|ƒWƒXƒg F â—‹å·ä¸Š 純一 S01-4 標的絶対定é‡çš„プãƒãƒ†ã‚ªãƒŸã‚¯ã‚¹ã«åŸºã¥ãPharmacoproteomics:国際共åŒç ”究ã®é‡è¦æ€§ Quantitative targeted absolute proteomics (QTAP) based pharmacoproteomics: Importance of international collaboration ƒVƒ“ƒ|ƒWƒXƒg F ○寺崎 哲也 S01-5 In silicoç ”ç©¶ã®è¦–点ã‹ã‚‰ From the viewpoint of in silico research ƒVƒ“ƒ|ƒWƒXƒg F ○奥野 æå² S01-6 薬物代è¬ç ”究ã®è¦–点ã‹ã‚‰ From the viewpoint of drug metabolism research ƒVƒ“ƒ|ƒWƒXƒg F â—‹ä¸å³¶ 美紀 ŒŸõƒy[ƒW‚É–ß‚é